ライフサイエンスコーパス: lymphoblastic lymphoma

1 (DK/DK) mice suffered from rapid-onset acute lymphoblastic lymphoma.

2 ic background, display a high rate of thymic lymphoblastic lymphoma.

3 transformation to acute myeloid leukemia and lymphoblastic lymphoma.

4 ansformation to acute myeloid leukemia and T-lymphoblastic lymphoma.

5 lopment of human multiple myeloma and T-cell lymphoblastic lymphoma.

6 -cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma.

7 e, were observed due to an aggressive T-cell lymphoblastic lymphoma.

8 ent treatment protocols for both T-ALL and T-lymphoblastic lymphoma.

9 ession, and a biopsy showed precursor B cell lymphoblastic lymphoma.

10 eas T/T(F) causes a long-latency, pre-B-cell lymphoblastic lymphoma.

11 therapy was effective only in patients with lymphoblastic lymphoma.

12 cute lymphoblastic leukemia (ALL) and T-cell lymphoblastic lymphoma.

13 ke cell line established from a patient with lymphoblastic lymphoma.

14 The patient's diagnosis was T-lymphoblastic lymphoma.

15 t only MASH but also liver infiltration of T-lymphoblastic lymphoma.

16 g adults (younger than 25 years) with ALL or lymphoblastic lymphoma.

17 c mechanism for extranodal infiltration of T-lymphoblastic lymphoma.

18 similar to most human and mouse T-cell acute lymphoblastic lymphomas.

19 tical in the inception of human T cell acute lymphoblastic lymphomas.

20 s not detected in either case of precursor B-lymphoblastic lymphomas.

21 two Burkitt's lymphomas, and two precursor B-lymphoblastic lymphomas.

22 39 eligible patients enrolled (230 ALL, nine lymphoblastic lymphoma); 120 were assigned to pegasparga

23 mall subset of XCGD GT mice developed T cell lymphoblastic lymphoma (2.94%) and myeloid leukemia (5.8

24 apsed Philadelphia chromosome-negative acute lymphoblastic lymphoma (ALL) is poor.

25 ts afflicted with this syndrome present with lymphoblastic lymphoma and a myeloproliferative disorder

26 omas), and 15 highly aggressive lymphomas (7 lymphoblastic lymphomas and 8 Burkitt's lymphomas).

27 rom small non-cleaved-cell lymphoma, 16 from lymphoblastic lymphoma, and five from large-cell lymphom

28 %, and 1% of small noncleaved cell lymphoma, lymphoblastic lymphoma, and large-cell cases, respective

29 pe of NHL that includes large-cell lymphoma, lymphoblastic lymphoma, and small noncleaved-cell lympho

30 th T-cell leukemia (T-ALL) or advanced stage lymphoblastic lymphoma (ASLL).

31 oblastic leukaemia (pre-B cell or T cell) or lymphoblastic lymphoma (B cell or T cell immunophenotype

32 hich progressed to TdT(+)CD20(-) precursor B-lymphoblastic lymphoma (B-LBL).

33 re less common in extramedullary tissue (BCP lymphoblastic lymphoma [BCP-LBL]).

34 All patients were treated with T-cell lymphoblastic lymphoma-Berlin-Frankfurt-Munster group (B

35 -cyclin-transgenic mice developed high-grade lymphoblastic lymphoma between 3 and 12 months of age.

36 -C3 mice develop aggressive malignant thymic lymphoblastic lymphomas between 4 and 8 months of age.

37 death (septic shock and natural killer-cell lymphoblastic lymphoma); both were related to treatment.

38 sm contributed to the aggressive growth of T-lymphoblastic lymphoma cells in MASH liver.

39 gnaling pathway activation were studied in T-lymphoblastic lymphoma cells.

40 T-cell acute lymphoblastic lymphomas commonly demonstrate activating

41 he role of STATs in an IL-2-responsive human lymphoblastic lymphoma-derived cell line, YT.

42 he oncogenic potential of Stat5, with thymic lymphoblastic lymphomas developing in a significant prop

43 pstein-Barr virus-negative, precursor B cell lymphoblastic lymphoma diagnosed 6 months after transpla

44 omas, mantle cell lymphomas, and precursor B-lymphoblastic lymphomas) expressed significant levels of

45 Precursor B cell lymphoblastic lymphoma has not been previously reported

46 manner across B-cell lymphoma, T-cell acute lymphoblastic lymphoma, hepatocellular carcinoma, renal

47 study, the genetic basis of GD/T-cell acute lymphoblastic lymphoma in 2 affected siblings was deciph

48 nt growth to Ba/F3 cells and caused a T-cell lymphoblastic lymphoma in a murine bone marrow transplan

49 The use of ASCT in adults with lymphoblastic lymphoma in first remission produced a tre

50 tic strategy against liver infiltration of T-lymphoblastic lymphoma in MASH liver.

51 We observed an increased incidence of T-lymphoblastic lymphoma in Runx1(lacZ/lacZ) compared with

52 naling contributed to aggressive growth of T-lymphoblastic lymphoma in vitro and in vivo.

53 now report the development of thymic T cell lymphoblastic lymphomas in transgenic mice in which Stat

54 ent-free survival (pEFS) in pediatric T-cell lymphoblastic lymphoma is about 80%, whereas survival in

55 Lymphoblastic lymphoma (LBL) is a rare, clinically aggre

56 about the outcome of pediatric patients with lymphoblastic lymphoma (LBL) who suffer from progressive

57 lymphoblastic leukemia [ALL], 13 of 21 T-ALL/lymphoblastic lymphomas [LBL], 9 of 10 B-non-Hodgkin's l

58 been shown in patients with precursor T-cell lymphoblastic lymphoma/leukemia (pre-T LBL).

59 en during embryonic development and in acute lymphoblastic lymphoma-like biphenotypic acute leukemias

60 Therapy of lymphoblastic lymphoma (LL) has evolved with use of chem

61 actory acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL) have poor outcomes compared

62 lastic leukemia (ALL) therapy in adults with lymphoblastic lymphoma (LL).

63 rose after therapy for one case of T-lineage lymphoblastic lymphoma (LyL) and two cases of acute lymp

64 e lymphoblastic leukaemia and two had B-cell lymphoblastic lymphoma; median age 41 years [IQR 32-50])

65 h relapsed or refractory B-ALL (n = 72) or B-lymphoblastic lymphoma (n = 2), treated in two cohorts:

66 These mice developed lymphoblastic lymphomas of both T and B lineage, demonst

67 ing the truncated protein develop large-cell lymphoblastic lymphomas of T-cell origin.

68 ural killer cell, or not-otherwise specified lymphoblastic lymphoma or leukaemia.

69 are neoplasms derived from immature T cells (lymphoblastic lymphomas), or more commonly, from mature

70 was not seen in small-cell T-cell lymphomas, lymphoblastic lymphomas, or other tumor types, including

71 developed spontaneous tumors, predominantly lymphoblastic lymphomas, similar to p53(-/-) mice.

72 ce demonstrate complete penetrance of thymic lymphoblastic lymphomas, strongly suggesting that Prkdc

73 ctivation in adult mice induces T-cell acute lymphoblastic lymphoma (T-ALL), a tumor type known to ca

74 ntribute to the pathogenesis of T cell acute lymphoblastic lymphoma (T-ALL), but how activated Notch1

75 sis as well as diseases such as T-cell acute lymphoblastic lymphoma (T-ALL).

76 eviously, precursor T lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LyL) was found to express

77 T-cell lymphoblastic lymphoma (T-LBL) and T-cell acute lymphobl

78 phoblastic leukemia (T-ALL) and T-cell acute lymphoblastic lymphoma (T-LBL) are aggressive hematologi

79 T-cell lymphoblastic lymphoma (T-LBL) is a heterogeneous malign

80 oblastic leukemia (T-ALL) and 13 with T-cell lymphoblastic lymphoma (T-LBL) with nelarabine.

81 tients with newly diagnosed pediatric T-cell lymphoblastic lymphoma (T-LL) and gained preliminary dat

82 Defining prognostic variables in T-lymphoblastic lymphoma (T-LL) remains a challenge.

83 in approximately 15% of children with T-cell lymphoblastic lymphoma (T-LL).

84 T-cell lymphoblastic lymphoma (T-LLy) and T-cell acute lymphobl

85 e lymphoblastic leukemia (T-ALL) or advanced lymphoblastic lymphoma (T-NHL) were randomized at diagno

86 Pediatric T-cell lymphoblastic lymphomas (T-LBL) are commonly treated on

87 We examined 8 precursor T-cell lymphoblastic lymphomas (T-LBLs) and found significant B

88 reases of lymphoblasts to overt monoclonal T-lymphoblastic lymphomas that involved multiple organs.

89 subjected TAp63 (+/-) or p73 (+/-) mice to T lymphoblastic lymphomas (TLBLs).

90 ng adults with relapsed/refractory CD19+ ALL/lymphoblastic lymphoma treated on 5 CD19-directed CAR T-

91 We identified patients with r/r CD19+ ALL/lymphoblastic lymphoma treated on CD19-directed CAR T-ce

92 cases of large cell lymphoma, five cases of lymphoblastic lymphoma, two cases of small, noncleaved-c

93 survival among the patients with early-stage lymphoblastic lymphoma was inferior to that among the pa

94 Tp53-deficient mouse model for T-cell acute lymphoblastic lymphoma, we reported that loss of heteroz

95 Fifteen patients with T-cell lymphoblastic lymphoma were also treated with the same h

96 Fourteen of 15 patients with T-cell lymphoblastic lymphoma were long-term survivors.

97 ge 1 to 21 years with newly diagnosed ALL or lymphoblastic lymphoma were randomly assigned to intrave

98 adult patients with newly diagnosed ALL and lymphoblastic lymphoma were treated with a dose-intense

99 n patients with acute lymphoblastic leukemia/lymphoblastic lymphoma who developed hypersensitivity/si

100 n with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma who received one of three CNS-dir

101 tive B-cell acute lymphoblastic leukaemia or lymphoblastic lymphoma with CD20 expression of at least